 1 (ISCO.OB) A New Kind of Stem Cell Company Superior Technology Superior Business Model Superior Execution Exhibit 99.1 |
 Statements pertaining to anticipated technological developments and therapeutic applications, the potential benefits of collaborations, affiliations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "should," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward- looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements. 2 Forward-looking statements |
 The Traditional Approach --Pick A Disease— --Spend a Lot of Money— --Hope for a Cure and FDA Approval-- 3 |
             The ISCO Model – Multiple Chances to Succeed 4 Parthenogenetic Stem Cells Parthenogenetic Stem Cells Lifeline Bioresearch Products Lifeline Bioresearch Products Stem Cell Bank Stem Cell Bank Lifeline Skin Care Products Lifeline Skin Care Products Therapeutic Development Therapeutic Development Partnering Partnering |
 Parthenogenesis – Solving Ethical and Immune Matching Problems 5 Normal fertilization Parthenogenesis |
 6 Categories of Human Stem Cells hpSCs Embryonic iPS Adult SCs Ethics (Relative to destruction of viable human embryos) No viable embryo Destroys viable embryo No embryo No embryo Immune matching and cell banking (practical source of cells) Population groups & individuals ( ) Impractical (each line is unique) Matched to individual only Matched to individual only Pluripotency (Become cells from all parts of body) Yes Yes Yes No Proliferation (Ease of expansion in culture) Strong Strong Strong Weak Genetic Manipulation (Restructuring of gene expression patterns) Minimal Minimal Substantial Minimal Application for Diseases with Genetic Component Superior Superior Deficient (carry damaged gene) Deficient (carry damaged gene) |
    7 Prioritized Therapeutic Areas Cornea transplant • 10M corneally blind • Untouched Asian/Indian markets • Can use either hpSCs or hESs Toxicity testing Retinal conditions - cell therapy is proven • Age-related macular degeneration (AMD) • Retinitis pigmentosa (RP)- 100,000 Americans and no therapy ISCO RPE technology • Demonstrated morphology, markers and pigmentation • In vivo functionality testing underway Liver diseases (acute and chronic) • 30-40M with fatty liver and app. 30,000 deaths annually in the US • 15,750 on liver waiting list ($200-$300k surgery, $12-20k annually) Neurodegenerative diseases • Cell therapy proven • Large unmet medical need • Increasing with the aging of the population ISCO objectives • Development of neuronal lineages • In vivo functional validation ISCO hepatocyte technology • Demonstrated markers and functionality • In vivo functionality testing underway |
 Universal Stem Cell Banking Every person has an immune type • There are 200 common types in a typical population Parthenogenetic stem cells: • Can be matched to millions of people • Example: 5 cell lines could match 42 million in the USA A “Bank” of these could provide immune-matched cells for millions at a cost they could afford For the Scientist |
 • Biomedical Products • >130 Products: growth factors, media and human cells • More new products in 2009-10 than the market-leader • cGMP media and cell manufacturing capacity Applications • Across therapeutic areas • Regenerative medicine (Stem Cell Products) • Safety and toxicology • Basic cell biology Commercialization • Direct sales from in-house staff (USA) • International Distribution: : Europe, Asia (incl.India) • OEM Partners: ATCC, Millipore, Life Technologies 9 |
 Development • Built on ISCO’s scientific expertise • Leverages proprietary technology platform • Clinically tested for safety and efficacy Commercialization • Market-differentiating stem cell technology • Direct-to-consumer and retail sales • Specialty distributor channels • Strategic marketing partnership 10 Baseline 6 weeks 16 weeks Lifeline Skin Care |
 12-month Targets 11 Lifeline Cell Technology • Expand Product Line, Foreign Manufacturing, and Distribution Base Lifeline Skin Care • Expand Sales Channels and Manufacturing Capacity Therapeutic Development • Animal Studies and IND Plan International Partnering • One or More Therapeutic Partnerships Human Parthenogenetic Stem Cell Bank • Created Multiple cGMP Parthenote Lines |
 Management Kenneth Aldrich, JD, Executive Chairman • 30 years investment in and management of public and private companies Dr. Andrey Semechkin, CEO • PhD, Member of Russian Academy of Sciences • Successful founder and manager of international companies Brian Lundstrom, President • Novo Nordisk, SangStat/Genzyme and ACADIA • 25 years clinical-commercial development and transactional experience Jeffrey Janus, SVP and CEO Lifeline Cell Technology • 25 years experience with cell-based and FDA-compliant biological products • Founder of Clonetics (now research product market leader Lonza) Dr. Ruslan Semechkin, VP and CEO Lifeline Skin Care • PhD, medical science and cosmeceutical development experience Dr. Simon Craw, VP • PhD, Executive with Merck, AstraZeneca and Novartis • 22 years scientific operational experience 12 |
 Financial overview 13 Shares outstanding 72 million Stock price (3-3-11) $1.50 Market capitalization $108 million Product revenue (Q-3, 2010 annualized) $1.4 million |
 14 Contact information www.internationalstemcell.com Kenneth Aldrich, Chairman 760-940-6383 kaldrich@intlstemcell.com |